NASDAQ:OTLK Outlook Therapeutics (OTLK) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free OTLK Stock Alerts $8.19 -0.01 (-0.12%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$7.85▼$8.3750-Day Range$5.73▼$11.9452-Week Range$4.00▼$40.60Volume150,455 shsAverage Volume530,385 shsMarket Capitalization$106.58 millionP/E RatioN/ADividend YieldN/APrice Target$46.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Outlook Therapeutics alerts: Email Address Outlook Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside466.8% Upside$46.43 Price TargetShort InterestHealthy7.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 5 Articles This WeekInsider TradingAcquiring Shares$22,245 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.99) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.83 out of 5 starsMedical Sector349th out of 907 stocksBiological Products, Except Diagnostic Industry49th out of 153 stocks 3.4 Analyst's Opinion Consensus RatingOutlook Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOutlook Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.41% of the float of Outlook Therapeutics has been sold short.Short Interest Ratio / Days to CoverOutlook Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Outlook Therapeutics has recently decreased by 15.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOutlook Therapeutics does not currently pay a dividend.Dividend GrowthOutlook Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OTLK. Previous Next 2.8 News and Social Media Coverage News SentimentOutlook Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Outlook Therapeutics this week, compared to 3 articles on an average week.Search Interest75 people have searched for OTLK on MarketBeat in the last 30 days. This is an increase of 188% compared to the previous 30 days.MarketBeat Follows18 people have added Outlook Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Outlook Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $22,245.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Outlook Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.20% of the stock of Outlook Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Outlook Therapeutics are expected to grow in the coming year, from ($2.99) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Outlook Therapeutics is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Outlook Therapeutics is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Outlook Therapeutics Stock (NASDAQ:OTLK)Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Read More OTLK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OTLK Stock News HeadlinesMarch 30, 2024 | insidertrades.comYezan Munther Haddadin Purchases 1,882 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) StockApril 22, 2024 | finance.yahoo.comBest's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to PositiveApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 22, 2024 | markets.businessinsider.comWGA Releases New Housing Finance OutlookApril 22, 2024 | msn.comOutlook: How to set up breaks between your meetingsApril 21, 2024 | finance.yahoo.comOutlook Therapeutics, Inc. (OTLK)April 18, 2024 | finance.yahoo.comWorld Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and PricesApril 18, 2024 | usnews.comBosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 15, 2024 | globenewswire.comOutlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 15, 2024 | americanbankingnews.comOutlook Therapeutics (NASDAQ:OTLK) versus Vigil Neuroscience (NASDAQ:VIGL) Head-To-Head ContrastApril 14, 2024 | msn.comMicrosoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot?April 14, 2024 | msn.comUS Consumer Sentiment Falls Slightly as Outlook for Inflation WorsensApril 11, 2024 | fxstreet.comFed's Williams: Outlook is uncertain, Fed must be data-dependentApril 11, 2024 | msn.comStock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate CutApril 11, 2024 | msn.comBitdefender now has identity protection for Gmail and OutlookApril 10, 2024 | finance.yahoo.comInsiders are Piling into These 10 Healthcare Stocks in 2024April 3, 2024 | forbes.comUsers Complain Gmail Blocks Email From Microsoft Outlook—Here’s The FixApril 3, 2024 | msn.comOutlook.com trips over Google's spam blocking rulesMarch 29, 2024 | uk.investing.comBTIG upgrades Outlook Therapeutics stock to buy, cites ONS-5010 successMarch 27, 2024 | markets.businessinsider.comBuy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price TargetMarch 27, 2024 | msn.comOutlook Therapeutics shares rise after 'buy' rating from BTIGMarch 25, 2024 | markets.businessinsider.comOutlook Therapeutics: Buy Rating Affirmed Amid Positive European Developments and Anticipated U.S. Market SuccessMarch 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Outlook Therapeutics: European Endorsement and Pivotal US Study Progress Signal Strong Market PotentialMarch 24, 2024 | nasdaq.comOutlook Therapeutics Surges On Positive CHMP Opinion For ONS-5010March 22, 2024 | msn.comWhy Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?See More Headlines Receive OTLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OTLK CUSIPN/A CIK1649989 Webwww.outlooktherapeutics.com Phone(609) 619-3990FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Target$46.43 High Stock Price Target$100.00 Low Stock Price Target$20.00 Potential Upside/Downside+486.9%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,741.39% Return on Assets-132.37% Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.11) per share Price / Book-7.13Miscellaneous Outstanding Shares13,010,000Free Float12,323,000Market Cap$102.91 million OptionableOptionable Beta0.04 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Ralph H. Thurman (Age 75)Independent Executive Chairman Comp: $207.5kMr. C. Russell Trenary III (Age 66)President, CEO & Director Comp: $610.9kMr. Lawrence A. Kenyon CPA (Age 58)Executive VP, CFO, Treasurer, Company Secretary & Director Mr. Jeffrey Evanson (Age 55)Chief Commercial Officer Comp: $451.17kMs. Alicia TozierSenior Vice President, Marketing & Market AccessMr. Joel PrieveSenior Vice President of Licensing and M&ADr. Surendra Sharma M.D.Senior Vice President of Medical AffairsDr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development & Regulatory AffairsMr. Jedd ComiskeySenior VP - Head of EuropeMore ExecutivesKey Competitorsbluebird bioNASDAQ:BLUEBioAtlaNASDAQ:BCABaTyr PharmaNASDAQ:LIFEVigil NeuroscienceNASDAQ:VIGLSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsYezan Munther HaddadinBought 1,882 shares on 3/28/2024Total: $22,245.24 ($11.82/share)Scotia Capital Inc.Sold 54,359 shares on 2/12/2024Ownership: 0.109%View All Insider TransactionsView All Institutional Transactions OTLK Stock Analysis - Frequently Asked Questions Should I buy or sell Outlook Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OTLK shares. View OTLK analyst ratings or view top-rated stocks. What is Outlook Therapeutics' stock price target for 2024? 8 Wall Street research analysts have issued 12-month price targets for Outlook Therapeutics' stock. Their OTLK share price targets range from $20.00 to $100.00. On average, they predict the company's share price to reach $46.43 in the next twelve months. This suggests a possible upside of 466.8% from the stock's current price. View analysts price targets for OTLK or view top-rated stocks among Wall Street analysts. How have OTLK shares performed in 2024? Outlook Therapeutics' stock was trading at $7.88 at the beginning of the year. Since then, OTLK stock has increased by 3.9% and is now trading at $8.19. View the best growth stocks for 2024 here. Are investors shorting Outlook Therapeutics? Outlook Therapeutics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 1,130,000 shares, a decline of 15.0% from the March 31st total of 1,330,000 shares. Based on an average daily trading volume, of 639,000 shares, the short-interest ratio is presently 1.8 days. Currently, 7.4% of the company's shares are short sold. View Outlook Therapeutics' Short Interest. When is Outlook Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our OTLK earnings forecast. How were Outlook Therapeutics' earnings last quarter? Outlook Therapeutics, Inc. (NASDAQ:OTLK) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.20. When did Outlook Therapeutics' stock split? Outlook Therapeutics's stock reverse split on Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Outlook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and CNBX Pharmaceuticals (CNBX). How do I buy shares of Outlook Therapeutics? Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OTLK) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
